[Marinir] {Disarmed} biOasis (TSX-V: BTI) Announces Transcend Vector Results with a Therapeutic Antibody That Targets Metastatic Breast Cancer

[Infostock]

 Click here
http://www.actonsoftware.com/acton/ct/1523/s-000a-1107/Bct/l-0002/l-0002:15bcd/ct0_1/1
 to view this message in a browser window

http://www.bioasis.ca 

Press Release - biOasis Technologies Inc. 

biOasis Announces Transcend Vector Results with a Therapeutic Antibody 
That Targets Metastatic Breast Cancer 

July 6 , 2011 

Vancouver, B.C. July 6, 2011 - biOasis Technologies Inc. (TSX:V.BTI) 
today announced results from two studies designed to assess the 
therapeutic potential of its Transcend vector in treating metastatic 
breast cancer. In these studies trastuzumab (tradename Herceptin), a 
humanized monoclonal antibody used clinically in the treatment of 
HER2-positive ("HER2+") breast cancer, was chemically linked to the 
Transcend delivery vector. The purpose of these studies was to assess if 
this conjugate can cross the blood-brain barrier and enter the tissue of 
the brain. And further, to test the effectiveness of the 
Transcend-trastuzumab conjugate (known as BT2111) against HER2+ cancer 
cells, verses trastuzumab on its own. 

In the first set of studies conducted for biOasis by the National 
Research Council of Canada (NRC), the transport of trastuzumab and 
BT2111 across the blood-brain barrier was compared using real-time 
fluorescence imaging. The results showed that trastuzumab does not 
actively enter human brain endothelial cells in vitro. This combined 
with the observation that trastuzumab does not actively cross the intact 
blood-brain barrier sufficient enough to reach therapeutic 
concentrations in animals, indicates that it would be difficult to use 
it as a therapeutic agent to target brain metastatic tumors. However, in 
the case of BT2111, there was a marked transport of the drug into human 
brain endothelial cells in vitro. 

In the second set of studies conducted on behalf of the Company by the 
BC Cancer Research Centre (BCCRC), various breast cancer cell lines were 
exposed in vitro to increasing doses of trastuzumab alone and to BT2111. 
In several HER2+ breast cancer cell lines, BT2111 demonstrated a 
significant improvement in cancer killing activity compared to 
trastuzumab alone. 

"Approximately 30% of breast cancers are HER2+. Although trastuzumab has 
proven valuable in the treatment and control of systemic disease, 
clinicians have observed a significant number of women with HER2+ cancer 
that exhibit central nervous system ("CNS") metastasis", said Rob 
Hutchison, CEO. "This combination of a tumour type that has a high 
potential for CNS metastases and existing treatment with trastuzumab 
that unfortunately does not penetrate the CNS, demonstrates the need for 
a carrier such as Transcend. Based on these initial results of the two 
recent studies, the Company has commissioned additional studies under 
the BT2111 program." 

ABOUT THE BLOOD-BRAIN BARRIER 

Overcoming the difficulty of delivering therapeutic agents to specific 
regions of the brain presents a major challenge in the treatment of most 
brain disorders. In its neuroprotective role, the blood-brain barrier 
functions to hinder the delivery of many potentially important 
therapeutic agents to the brain. Therapeutic molecules that might 
otherwise be effective in the treatment of CNS conditions do not cross 
the blood-brain barrier in adequate amounts. 

It is widely reported that over 95% of all Therapeutic molecules do not 
cross the blood-brain barrier. 

ABOUT TRANSCEND 

biOasis is developing a proprietary carrier for the transport of 
therapeutic and imaging agents across the blood-brain barrier - 
Transcend. Current initiatives within the Transcend program include 
production of materials for preclinical studies and conjugation to a 
range of small molecule and biologic therapeutics. To address the unmet 
clinical need to transport drugs across the blood brain barrier biOasis 
intends to license Transcend to multiple corporate partners. 

ABOUT BIOASIS: 

biOasis Technologies Inc. is a biopharmaceutical company engaged in the 
development and commercialization of products for the diagnosis and 
treatment of neurological diseases and disorders. Its products and 
technologies are intended for use within the healthcare and life science 
research markets. The Company is currently developing Cognitest™, 
a blood test for the diagnosis of Alzheimer's disease. biOasis is also 
developing Transcend, a proprietary molecular carrier intended to 
transport drugs across the Blood-Brain Barrier for treatment of a wide 
range of neurological, oncological and infectious disease applications. 

Forward Looking Statements 

Certain statements in this press release contain forward-looking 
statements within the meaning of the Private Securities Litigation 
Reform Act of 1995 or forward-looking information under applicable 
Canadian securities legislation that may not be based on historical 
fact, including without limitation statements containing the words 
"believe", "may", "plan", "will", "estimate", "continue", "anticipate", 
"intend", "expect" and similar expressions. Such forward-looking 
statements or information involve known and unknown risks, uncertainties 
and other factors that may cause our actual results, events or 
developments, or industry results, to be materially different from any 
future results, events or developments express or implied by such 
forward-looking statements or information. Such factors include, among 
others, our stage of development, lack of any product revenues, 
additional capital requirements, risk associated with the completion of 
clinical trials and obtaining regulatory approval to market our 
products, the ability to protect our intellectual property, dependence 
on collaborative partners and the prospects for negotiating additional 
corporate collaborations or licensing arrangements and their timing. 
Specifically, certain risks and uncertainties that could cause such 
actual events or results expressed or implied by such forward-looking 
statements and information to differ materially from any future events 
or results expressed or implied by such statements and information 
include, but are not limited to, the risks and uncertainties that: we 
may not be able to successfully develop and obtain regulatory approval 
for p97 as a Physician's Aid to Diagnose Alzheimer's, or future products 
in our targeted corporate objectives; our future operating results are 
uncertain and likely to fluctuate; we may not be able to raise 
additional capital; we may not be successful in establishing additional 
corporate collaborations or licensing arrangements; we may not be able 
to establish marketing and the costs of launching our products may be 
greater than anticipated; we have no experience in commercial 
manufacturing; we may face unknown risks related to intellectual 
property matters; we face increased competition from pharmaceutical and 
biotechnology companies; and other factors as described in detail in our 
filings with the Canadian securities regulatory authorities at 
www.sedar.com. Given these risks and uncertainties, you are cautioned 
not to place undue reliance on such forward-looking statements and 
information, which are qualified in their entirety by this cautionary 
statement. All forward-looking statements and information made herein 
are based on our current expectations and we undertake no obligation to 
revise or update such forward- looking statements and information to 
reflect subsequent events or circumstances, except as required by law. 

On Behalf of the Board of Directors 

Rob Hutchison Chairman & CEO 

(778).383.3280 

rob at bioasis.ca 

"Neither the TSX Venture Exchange nor its Regulation Services Provider 
(as that term is defined in the policies of the TSX Venture Exchange) 
accepts responsibility for the adequacy or accuracy of this release" 

Visit biOasis Technologies Inc. Website: www.bioasis.ca 

http://app.simplycast.com/script/redirect.php?e=5189&outgoing_idno=5852091&gId=5761863&link_idno=5740102 

--------------------------------------------------------------------------------
*********************************************************************
Disclaimer: KCrew Communications was paid to distribute this Infostock bulletin.
KCrew Communications may or may not own securities in this particular company.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
You are on this mailing list because you registered for Infostock.
You may opt out at any time using the unsubscribe feature at the bottom of this email.
For more information about this service, please see http://www.infostockbiz.com
http://www.infostockbiz.com

KCrew Communications Inc. at 1.866.465.3616
Suite 1250 - 789 West Pender St., Vancouver, BC Canada V6C1H2.
This email complies with the US Federal CAN-SPAM Act of 2003
*********************************************************************

If you do not wish to receive futher emails Click Here
http://www.actonsoftware.com/acton/rif/1523/s-000a-1107/-/l-0002:15bcd/l-0002/zout
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.polarhome.com/pipermail/munindo/attachments/20110706/e0dbc06e/attachment.html>